Maxigen Biotech Inc.

Total Valuation

Maxigen Biotech Inc. carries a market capitalization of 3.64B, placing it among publicly traded companies globally. Its enterprise value stands at 3.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Maxigen Biotech Inc. currently has 89.68M shares outstanding.

Valuation Ratios

Maxigen Biotech Inc. trades at a trailing price-to-earnings ratio of 14.46. The price-to-sales ratio is 4.73, and the price-to-book ratio stands at 3.30.

Enterprise Valuation

On an enterprise value basis, Maxigen Biotech Inc. trades at an EV/EBITDA multiple of 12.06 and an EV/FCF ratio of 8.22. The EV/Sales ratio of 3.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.06 provides insight into valuation relative to core operating earnings.

Financial Position

Maxigen Biotech Inc. maintains a current ratio of 3.21, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Maxigen Biotech Inc. posts a return on equity of 23.32 and a return on invested capital of 14.39.

Taxes

Over the trailing twelve months, Maxigen Biotech Inc. has paid 39.58M in income taxes, reflecting an effective tax rate of 12.98.

Stock Price Statistics

Maxigen Biotech Inc.'s stock has declined approximately -6.66667% over the past 52 weeks. The 50-day moving average sits at 38.94, while the 200-day moving average is 42.64.

Income Statement

Over the trailing twelve months, Maxigen Biotech Inc. generated 811.56M in revenue and converted that into 265.31M in net income, yielding earnings per share of 2.95. EBITDA reached 253.72M, while operating income came in at 253.72M.

Balance Sheet

Maxigen Biotech Inc. holds 877.69M in cash and equivalents against 101.40M in total debt, resulting in a net debt position of -474.79M. Total book value stands at 1.16B, with working capital of 772.36M providing operational flexibility.

Cash Flow

Maxigen Biotech Inc. produced 290.22M in operating cash flow over the past twelve months. After subtracting -81.93M in capital expenditures, free cash flow totaled 208.29M - equivalent to 2.32 per share.

Margins

Maxigen Biotech Inc. operates with a gross margin of 69.46, reflecting its pricing power and cost economics. The operating margin of 31.26 and net profit margin of 32.69 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Maxigen Biotech Inc.'s most recent stock split took place on September 7, 2023 with a 20:21 split ratio.

Scores

Maxigen Biotech Inc. posts an Altman Z-Score of 8.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.